{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:47:19Z","timestamp":1766180839752},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0142378","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T18:28:32Z","timestamp":1457720912000},"page":"e0142378","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels"],"prefix":"10.1371","volume":"11","author":[{"given":"Cheng-Kung","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Mo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0168-8278(03)00018-7","article-title":"HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy","volume":"38","author":"C Puoti","year":"2003","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.510290219","article-title":"A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use","volume":"29","author":"TV Inglesby","year":"1999","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1590-8658(00)80850-6","article-title":"HCV carriers with normal aminotransferase levels: healthy people or true patients?","volume":"32","author":"C Puoti","year":"2000","journal-title":"Dig Liver Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gut.37.2.274","article-title":"Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases","volume":"37","author":"J Healey C","year":"1995","journal-title":"Gut"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1478-3231.2008.01733.x","article-title":"Is serumalanine transaminase level a reliable markerof histological disease in chronic hepatitis C infection?","volume":"28","author":"FM Sanai","year":"2008","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cgh.2006.02.002","article-title":"Chronic Hepatitis C in patients with persistently normal alanine aminotransferase levels","volume":"6","author":"ML Shiffman","year":"2006","journal-title":"Clin Gastronterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0168-8278(03)00004-7","article-title":"A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated aminotransferase","volume":"38","author":"CK Hui","year":"2003","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jhep.2008.11.019","article-title":"Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels","volume":"50","author":"T Kumada","year":"2009","journal-title":"J Hepatol"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1572-0241.2003.07539.x","article-title":"Liver Histology and Progression of Fibrosis in Individuals With Chronic Hepatitis C and Persistently Normal ALT","volume":"98","author":"I Kyrlagkitsis","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"GM Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group","volume":"339","author":"JG McHutchison","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2036.2007.03294.x","article-title":"Cochrane Systematic Review: Pegylated Interferon Plus Ribavirin vs Interferon Plus Ribavirin for Chronic Hepatitis C","volume":"25","author":"M Simin","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1478-3231.2006.01358a.x","article-title":"A 24-week course of high-dose interferon-a plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels","volume":"26","author":"ML Yu","year":"2006","journal-title":"Liver Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"133S","DOI":"10.1002\/hep.510260723","article-title":"Therapy of hepatitis C: patients with normal aminotransferase levels","volume":"26","author":"P Marcellin","year":"1997","journal-title":"Hepatology"},{"key":"ref15","first-page":"956","article-title":"Treatment in patients with normal ALT levels. European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis C","volume":"30","author":"NC Tassopoulos","year":"1999","journal-title":"J Hepatol"},{"key":"ref16","first-page":"202","article-title":"Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis","volume":"38","author":"CH Hung","year":"2003","journal-title":"J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"J Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"J Bruix","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: An Update","volume":"53","author":"J Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1002\/hep.1840360723","article-title":"Treatment of patients with Hepatitis C and normal serum aminotransferase levels","volume":"36","author":"BR Bacon","year":"2002","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/hep.510300526","article-title":"Clinical features of Hepatitis C-infected patients with persistently normal alanine aminotransferase levels in the Southwestern United States","volume":"30","author":"MM Jamal","year":"1999","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2005.04.008","article-title":"A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase","volume":"43","author":"T Okanoue","year":"2005","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2893.2005.00667.x","article-title":"Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years","volume":"13","author":"M Persico","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1365-2036.2007.03318.x","article-title":"Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels","volume":"25","author":"CK Hui","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.dld.2009.08.001","article-title":"Treatment of patients with normal ALT levels. In Practice guidelines for the treatment of hepatitis C: recommendations from an Expert Opinion Meeting","volume":"42","author":"C Puoti","year":"2010","journal-title":"Dig Liver Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"VJ Desmet","year":"1994","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1440-1746.2005.04059.x","article-title":"Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon \u03b1-2a (40 kDa) plus ribavirin: Impact on health-related quality of life","volume":"21","author":"S Arora","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2005.00700.x","article-title":"The economics of treating chronic hepatitis C patients with peginterferon a-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase","volume":"13","author":"J Hornberger","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1572-0241.2004.30049.x","article-title":"Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT","volume":"99","author":"IM Jaconson","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1053\/j.gastro.2004.09.050","article-title":"Peginterferon Alpha-2a (40 kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels","volume":"127","author":"S Zeuzem","year":"2004","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.23159","article-title":"Impact of Pegylated-interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France","volume":"50","author":"DB Sylvie","year":"2009","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0142378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:47:32Z","timestamp":1589042852000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0142378"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,11]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0142378","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,11]]}}}